芪苈强心胶囊对慢性心力衰竭患者血清钠影响临床研究

Effect of Qili Qiangxin Capsules on Serum Sodium in Patients with chronic Heart Failure

目的:观察芪苈强心胶囊治疗慢性心力衰竭的疗效及血清钠水平的变化。方法:对73例符合入选标准的心力衰竭患者,随机数字表法分为治疗组37例和对照组36例。对照组给予地高辛、血管紧张素转换酶抑制剂(ACE)I或血管紧张素Ⅱ受体拮抗剂(ARB)、呋噻米和螺内酯、β-受体阻滞剂的常规治疗。治疗组在对照组基础上加用芪苈强心胶囊治疗。观察2组患者治疗1周后心功能改善效果和治疗前、治疗1周后、1月后血清肌酐和血清钠浓度变化。结果:2组临床疗效比较,差异有显著性意义(P<0.05)。2组治疗1周后、1月后血清肌酐水平比较,差异均无显著性意义(P>0.05)。治疗1月后,2组血清钠比较,差异有显著性意义(P<0.05)。结论:在常规应用洋地黄、ACEI或ARB、β-受体阻滞剂、醛固酮拮抗剂、利尿剂的基础上,加用芪苈强心胶囊可提高疗效,降低低钠血症的发生率。

Objective： To investigate the change of serum sodium in patients with chronic heart failure and to observe the therapeutic effect of QiE Qiangxi Capsules. Methods： Seventy-three patients with heart failure were recruited and randomlied to experimental group （n=37） and control Oroup （n=36）. In the control group, conventional treatment with Digoxin, angiotensin-converting enzyme inhibitor（ACEI） or adrenergic receptor binder （ARB）, furosemide and spironolactone, and beta-blocker was carried out. Onn the basis of conventional treatment, Qili Qiangxin Capsules were given to the patients in experimental group. After treatment for one week, the improvement of cardiac function was evaluated, and the levels of serum creatinine and sodium were observed before treatment, one week and one＇month after treatment. Results： In the experimental group, the total effective rate was 94.59%, higher than 86.11% in the control group（P〈 0.05） The difference of serum creatinine between the two group was insignificant one week and one month after treatment, but serum sodium in the control group was significantly lower than that in experimental group in one month after treatment（P〈 0.05）. Conclusion： For the patients with heart failure, the application of oral use of Qili Qiangxin Capsules on the basis of conventional treatment can improve the therapeutic effect and reduce the incidence of hyponatremia.